EPRX

Eupraxia Pharmaceuticals Inc. Health Care Pharmaceutical Preparations Russell 3000

$6.83Close $354.7MMarket cap $5.33 – $9.1052-week range Nov 3, 2026Next report

Highlights

Cautions

Not in an uptrend 2 of 8 trend conditions
Lagging the market RS 45 · weaker than 55% of stocks over 12 months
Results soon Nov 3, 2026, in 2 days

Price

Filing Results Screen pick 52-week high and low Adjusted prices

Key figures

FY to Dec 31, 2025 · filed Mar 13, 2026

Off 12-month high 25%

1wk 0.6% price change

1mo 24.9% price change

12-month return 28% market up 11% · its own up 15%

F-score — — Not assessed

Altman Z 34.19 Low risk

P/E — price / earnings

PEG — P/E / EPS growth

P/B 4.3× price / book

Earnings yield 14.1% EBIT / enterprise value

Cheaper than 18% of the market · expensive

Revenue growth — year on year

EPS growth — latest quarter

Sales growth — latest quarter

ROE 67% return on equity

Free cash margin — -$28.6M FCF

D/E 0.00 long-term debt / equity

Net debt / EBITDA —

Interest cover —EBIT / interest

Trade setup

ATR% 7.7% $0.52 a day · 2×ATR $5.78

RS 45 / 99 vs the universe

Trend 2 / 8 trend template

Relative volume 1.7× vs 50-day average

Up/down volume 0.85 50 sessions

Implied move — no option chain · report Nov 3, 2026

Contractions 2 30% → 19%

Pivot $7.94 14.0% below

Volume dry-up 0.8× 10 vs 50 sessions

Trend template · 2 of 8

50-day average above the 150 and 200-day: passes
Within 25% of the 52-week high: passes

Screen verdict

Did not qualify for any screen.

Warning signs

1 flagged

Shareholders diluted The share count rose 45.7% over the year, from 36m to 52m shares. Each existing share owns a smaller fraction of the company than it did a year ago.

Last shock Oct 1, 2026-14% in one session6.5× volumeno filing matched-13% since

Financials

4 fiscal years · from filings

Revenue What customers paid the company over its fiscal year, before any cost, as filed in its annual report. The change is against the year before. Methodology $0

Net income Profit left after every cost, interest and tax for the year. A column below the line is a loss. Methodology -$38.6M

Free cash flow Cash from running the business less what it spent on equipment and buildings: the cash a year actually left behind, which profit alone does not show. Not shown for banks and insurers, whose cash moves with their loans. Methodology -$28.6M

Cash and long-term debt Cash on the balance sheet at the year's end beside debt due after a year. Net cash is cash less that debt; net debt is the shortfall. Debt some filers do not tag shows as a gap, not as zero. Methodology $80.6M net cash

Cash
Long-term debt

Shares outstanding Shares in issue at the year's end. A rising count means each share owns a smaller slice of the company (stock pay, share sales); a falling one, buybacks. The chart's scale is fitted to the count, so a small change looks large: read the percentage. Methodology 51.94m +140.5% since FY2022

	FY2022Dec 31, 2022	FY2023Dec 31, 2023	FY2024Dec 31, 2024	FY2025Dec 31, 2025
Revenue	—	$0	$0	$0
Net income	-$18.5M	-$28.2M	-$25.5M	-$38.6M
Earnings per share	-$0.96	-$1.17	-$0.75	-$0.97
Free cash flow	-$14.4M	-$20.7M	-$30.0M	-$28.6M
Cash	$18.3M	$19.3M	$33.1M	$80.6M
Long-term debt	$62,709	$0	$0	$0
Shareholders' equity	$7.8M	$2.2M	$33.4M	$82.0M
Shares outstanding	21.59m	27.28m	35.64m	51.94m

Filings

SEC EDGAR

Filed	Report	Period to	Lag
Mar 13, 2026	Annual ↗	Dec 31, 2025	72d
Mar 20, 2025	Annual ↗	Dec 31, 2024	79d
Apr 1, 2024	Annual ↗	Dec 31, 2023	92d

Current reports

Filed	Disclosed
Oct 22, 2026	Foreign issuer report ↗
Oct 15, 2026	Foreign issuer report ↗
Oct 9, 2026	Foreign issuer report ↗
Sep 30, 2026	Foreign issuer report ↗
Sep 8, 2026	Foreign issuer report ↗
Aug 13, 2026	Foreign issuer report ↗
Aug 11, 2026	Foreign issuer report ↗
Jul 15, 2026	Foreign issuer report ↗
Jul 13, 2026	Foreign issuer report ↗
Jul 7, 2026	Foreign issuer report ↗
Jun 22, 2026	Foreign issuer report ↗
May 29, 2026	Foreign issuer report ↗